Emerging Markets Report - Biotricity’s Bioflux RMT a Critical Tool in Reducing Fatalities Among COVID-19 Patients - Seite 2

Market Outlook

Over the last month, Biotricity’s stock price has been establishing a base within the range of $0.72 (support) and $1.08 (resistance), reversing the month-long downtrend from its February high of $2.21 per share. BTCY’s market cap stands at 35.636M, supported by an influx of buying pressure on February 28 following its Q4 net revenue report, showing a year-over-year increase of 224.63%. From a technical perspective, BTCY is basing near its 61.8% Fibonacci retracement, a key level which may indicate an opportune moment for buyers to begin accumulating shares. To date, volatility remains relatively low with no large increase in selling pressure.

As a leader in the biometric monitoring technology space, one that can play a significant role in the efforts toward treating COVID-19 patients, Biotricity is in a position to make its presence known to a larger number of institutional and retail investors. Biotrinity has plenty of room for expansion in operational capacity, market share, and revenue potential, making the company an investment case worth considering.

About Biotricity Inc.

Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.

The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.